Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor- Expressing Advanced Solid Tumors
ZYME Stock | USD 14.09 0.33 2.29% |
About 73% of Zymeworks Common's investor base is looking to short. The analysis of the overall investor sentiment regarding Zymeworks Common Stock suggests that many traders are alarmed. The current market sentiment, together with Zymeworks Common's historical and current headlines, can help investors time the market. In addition, many technical investors use Zymeworks Common Stock stock news signals to limit their universe of possible portfolio assets.
Zymeworks |
Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancersVANCOUVER, British Columbia, Nov. 05, 2024 -- Zymeworks Inc. , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the first patient has been dosed
Read at finance.yahoo.com
Zymeworks Common Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Zymeworks Common can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Zymeworks Common Fundamental Analysis
We analyze Zymeworks Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zymeworks Common using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zymeworks Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Zymeworks Common is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Zymeworks Common Stock Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Zymeworks Common stock to make a market-neutral strategy. Peer analysis of Zymeworks Common could also be used in its relative valuation, which is a method of valuing Zymeworks Common by comparing valuation metrics with similar companies.
Peers
Zymeworks Common Related Equities
CABA | Cabaletta Bio | 26.91 | ||||
BLUE | Bluebird Bio | 7.89 | ||||
PRQR | ProQR Therapeutics | 4.63 | ||||
MRSN | Mersana Therapeutics | 4.11 | ||||
EDIT | Editas Medicine | 1.82 | ||||
STOK | Stoke Therapeutics | 1.68 | ||||
ALEC | Alector | 1.57 | ||||
DAWN | Day One | 1.53 | ||||
BPMC | Blueprint Medicines | 1.35 | ||||
SNDX | Syndax Pharmaceuticals | 1.27 | ||||
ANNX | Annexon | 0.94 | ||||
TVTX | Travere Therapeutics | 0.59 | ||||
YMAB | Y MAbs | 0.34 | ||||
AKRO | Akero Therapeutics | 0.22 | ||||
INZY | Inozyme Pharma | 0.37 | ||||
ARWR | Arrowhead Pharmaceuticals | 0.46 | ||||
ZNTL | Zentalis Pharmaceuticals | 0.55 | ||||
APLS | Apellis Pharmaceuticals | 0.62 | ||||
CYTK | Cytokinetics | 0.69 | ||||
RVMD | Revolution Medicines | 1.25 | ||||
TERN | Terns Pharmaceuticals | 1.58 | ||||
RLAY | Relay Therapeutics | 2.08 | ||||
PTGX | Protagonist Therapeutics | 2.56 |
Complementary Tools for Zymeworks Stock analysis
When running Zymeworks Common's price analysis, check to measure Zymeworks Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zymeworks Common is operating at the current time. Most of Zymeworks Common's value examination focuses on studying past and present price action to predict the probability of Zymeworks Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zymeworks Common's price. Additionally, you may evaluate how the addition of Zymeworks Common to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |